Analysts Set Biogen Inc. (NASDAQ:BIIB) Target Price at $184.88

Biogen Inc. (NASDAQ:BIIB) has been assigned an average rating of “Hold” from the twenty-six analysts that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and ten have assigned a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $187.8077.

A number of research analysts recently weighed in on the stock. Wedbush raised their price target on shares of Biogen from $135.00 to $143.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Citigroup lifted their target price on shares of Biogen from $153.00 to $180.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 7th. Mizuho boosted their target price on Biogen from $169.00 to $177.00 and gave the stock an “outperform” rating in a research note on Monday, November 3rd. Hsbc Global Res downgraded Biogen from a “hold” rating to a “moderate sell” rating in a research report on Wednesday, December 10th. Finally, William Blair reissued an “outperform” rating on shares of Biogen in a research report on Wednesday, September 24th.

Biogen Stock Down 1.1%

BIIB stock opened at $185.63 on Thursday. The firm has a market capitalization of $27.23 billion, a PE ratio of 16.92, a P/E/G ratio of 1.56 and a beta of 0.13. The company has a quick ratio of 2.04, a current ratio of 2.72 and a debt-to-equity ratio of 0.35. Biogen has a twelve month low of $110.04 and a twelve month high of $190.20. The stock’s 50 day moving average is $173.73 and its 200-day moving average is $150.98.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Thursday, October 30th. The biotechnology company reported $4.81 EPS for the quarter, beating analysts’ consensus estimates of $3.89 by $0.92. Biogen had a return on equity of 14.13% and a net margin of 15.98%.The business had revenue of $2.53 billion during the quarter, compared to analyst estimates of $2.34 billion. During the same period in the prior year, the firm posted $4.08 EPS. Biogen’s quarterly revenue was up 2.8% compared to the same quarter last year. Biogen has set its FY 2025 guidance at 14.500-15.00 EPS. Sell-side analysts expect that Biogen will post 15.83 EPS for the current fiscal year.

Hedge Funds Weigh In On Biogen

Institutional investors have recently added to or reduced their stakes in the stock. Elevation Point Wealth Partners LLC purchased a new position in Biogen in the second quarter valued at about $25,000. Rothschild Investment LLC raised its holdings in shares of Biogen by 64.7% in the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 88 shares during the period. Accredited Wealth Management LLC lifted its stake in Biogen by 1,233.3% in the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 185 shares during the last quarter. Concord Wealth Partners lifted its stake in Biogen by 100.0% in the second quarter. Concord Wealth Partners now owns 228 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 114 shares during the last quarter. Finally, NewSquare Capital LLC grew its holdings in Biogen by 134.6% during the second quarter. NewSquare Capital LLC now owns 244 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 140 shares during the period. Institutional investors own 87.93% of the company’s stock.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.